Spinal muscular atrophy: from rags to riches
- PMID: 34736637
- DOI: 10.1016/j.nmd.2021.08.009
Spinal muscular atrophy: from rags to riches
Abstract
The aim of this paper is to provide a short history of spinal muscular atrophy, from the first descriptions of the disease to the impact of the most recent therapeutical advances on the disease course. The paper provides an overview of how the field has progressed over the years after the availability of care recommendations and, more recently of the new therapies. The paper also highlights the new challenges related to the interpretation of the efficacy of the new therapies and how these are likely to affect several aspects such as the classification of spinal muscular atrophy. We will also discuss the need for further work to better define possible new phenotypes and new methods of assessments and how these should be reflected in the care recommendations. The results in presymptomatic patients will finally highlight the need for neonatal screening.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Eugenio Mercuri reports personal fees from NOVARTIS/AVEXIS, ROCHE, BIOGEN S.R.L., SCHOLAR ROCK for advisory boards and as PI, outside the submitted work. He is affiliated to an institution that receives funds for a SMA disease registry (ISMAR);
Similar articles
-
Spinal muscular atrophy: a timely review.Arch Neurol. 2011 Aug;68(8):979-84. doi: 10.1001/archneurol.2011.74. Epub 2011 Apr 11. Arch Neurol. 2011. PMID: 21482919 Free PMC article.
-
Bulbospinal muscular atrophy: Kennedy's disease.Arch Neurol. 2004 Aug;61(8):1324-6. doi: 10.1001/archneur.61.8.1324. Arch Neurol. 2004. PMID: 15313856 No abstract available.
-
Treating neonatal spinal muscular atrophy: A 21st century success story?Early Hum Dev. 2019 Nov;138:104851. doi: 10.1016/j.earlhumdev.2019.104851. Epub 2019 Oct 8. Early Hum Dev. 2019. PMID: 31604576 Review.
-
[Gene-based therapies of spinal muscular atrophy: a piece of history of medicine].Med Sci (Paris). 2020 Feb;36(2):141-146. doi: 10.1051/medsci/2020011. Epub 2020 Mar 4. Med Sci (Paris). 2020. PMID: 32129750 Review. French.
-
[Expert consensus on newborn screening for spinal muscular atrophy (2023 edition)].Zhonghua Yi Xue Za Zhi. 2023 Jul 18;103(27):2075-2081. doi: 10.3760/cma.j.cn112137-20230310-00372. Zhonghua Yi Xue Za Zhi. 2023. PMID: 37455125 Chinese.
Cited by
-
Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.Gene Ther. 2023 Aug;30(7-8):592-597. doi: 10.1038/s41434-022-00341-6. Epub 2022 May 24. Gene Ther. 2023. PMID: 35606491 Free PMC article.
-
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.Int J Mol Sci. 2024 Aug 12;25(16):8763. doi: 10.3390/ijms25168763. Int J Mol Sci. 2024. PMID: 39201450 Free PMC article.
-
The various forms of hereditary motor neuron disorders and their historical descriptions.J Neurol. 2024 Jul;271(7):3978-3990. doi: 10.1007/s00415-024-12462-6. Epub 2024 May 30. J Neurol. 2024. PMID: 38816479 Review.
-
Sequential treatment with nusinersen, Zolgensma® and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report.Acta Myol. 2023 Sep 30;42(2-3):82-85. doi: 10.36185/2532-1900-356. eCollection 2023. Acta Myol. 2023. PMID: 38090542 Free PMC article.
-
Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy.Clin Drug Investig. 2024 Sep;44(9):687-701. doi: 10.1007/s40261-024-01386-8. Epub 2024 Aug 22. Clin Drug Investig. 2024. PMID: 39172297 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical